Trial Profile
A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs ASC-09/ritonavir (Primary) ; Lopinavir/ritonavir
- Indications Coronavirus infections; COVID 2019 infections
- Focus Adverse reactions
- 23 Mar 2022 Status changed from not yet recruiting to discontinued.
- 17 Feb 2020 New trial record